Pci Biotech Holding Stock Net Income
| PCIB Stock | NOK 1.90 0.58 43.94% |
PCI Biotech Holding fundamentals help investors to digest information that contributes to PCI Biotech's financial success or failures. It also enables traders to predict the movement of PCI Stock. The fundamental analysis module provides a way to measure PCI Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PCI Biotech stock.
PCI |
PCI Biotech Holding Company Net Income Analysis
PCI Biotech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current PCI Biotech Net Income | (88.39 M) |
Most of PCI Biotech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PCI Biotech Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, PCI Biotech Holding reported net income of (88.39 Million). This is 125.9% lower than that of the Biotechnology sector and 226.19% lower than that of the Health Care industry. The net income for all Norway stocks is 115.48% higher than that of the company.
PCI Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PCI Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PCI Biotech could also be used in its relative valuation, which is a method of valuing PCI Biotech by comparing valuation metrics of similar companies.PCI Biotech is currently under evaluation in net income category among its peers.
PCI Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (15.29) % | |||
| Current Valuation | 25.47 M | |||
| Shares Outstanding | 37.33 M | |||
| Shares Owned By Insiders | 31.97 % | |||
| Shares Owned By Institutions | 6.90 % | |||
| Price To Earning | (10.88) X | |||
| Price To Book | 1.44 X | |||
| Price To Sales | 18.74 X | |||
| Revenue | 6.27 M | |||
| Gross Profit | 6.27 M | |||
| EBITDA | (85.76 M) | |||
| Net Income | (88.39 M) | |||
| Cash And Equivalents | 116.12 M | |||
| Cash Per Share | 8.83 X | |||
| Total Debt | 1.28 M | |||
| Debt To Equity | 0.50 % | |||
| Current Ratio | 16.24 X | |||
| Book Value Per Share | 1.70 X | |||
| Cash Flow From Operations | (68.31 M) | |||
| Earnings Per Share | (2.35) X | |||
| Target Price | 24.0 | |||
| Number Of Employees | 14 | |||
| Beta | 1.86 | |||
| Market Capitalization | 81.93 M | |||
| Total Asset | 135.98 M | |||
| Working Capital | 38 M | |||
| Current Asset | 48 M | |||
| Current Liabilities | 10 M | |||
| Z Score | 38.4 | |||
| Net Asset | 135.98 M |
About PCI Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PCI Biotech Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PCI Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PCI Biotech Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in PCI Stock
PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.